Experimental Test Reveals Heart Attack And Stroke Risk
Researchers have introduced a new genetic test designed to assess an individual’s risk of developing severe blood clots. According to a study published on August 20 in Nature Communications, this experimental test measures platelet hyperreactivity, which can significantly increase the likelihood of experiencing heart attacks, strokes, and major amputations, particularly following procedures to clear blocked arteries in the legs.
The test evaluates whether a person’s platelets are excessively reactive, which can lead to abnormal clot formation. High scores on this test were linked to more than double the incidence of adverse cardiovascular events compared to those with lower scores. Dr. Jeffrey Berger, a leading researcher from NYU Grossman School of Medicine, highlighted that the test could reliably predict platelet hyperreactivity and its associated risks.
Currently, aspirin is often used to manage platelet activity based on broader risk factors like high cholesterol or blood pressure. However, this approach has its drawbacks, including an increased risk of bleeding. The new test aims to improve treatment precision by identifying individuals with hyperreactive platelets who are most likely to benefit from targeted anti-platelet therapy, potentially minimizing unnecessary treatment and its risks.
To develop this test, researchers analyzed genetic data from patients with known platelet hyperreactivity and identified specific genetic markers. These markers were used to create the Platelet Reactivity ExpresSion Score (PRESS). The PRESS test was then applied to patients who had undergone artery-clearing procedures, revealing that those with high PRESS scores faced significantly higher risks of severe cardiovascular outcomes.
In addition, the PRESS test was also used to evaluate women with clogged leg arteries. Results indicated that those with elevated scores had a 90% higher chance of experiencing heart attacks or strokes. This test has the potential to enhance the precision of cardiovascular risk assessments and improve the effectiveness of preventive treatments by focusing on those who need them most.
Discussion about this post